O	0	10	Advantages
O	11	15	with
O	16	28	prophylactic
B-intervention	29	32	PEG
I-intervention	32	33	-
I-intervention	33	36	rhG
I-intervention	36	37	-
I-intervention	37	40	CSF
O	41	47	versus
B-control	48	51	rhG
I-control	51	52	-
I-control	52	55	CSF
O	56	58	in
B-eligibility	59	65	breast
I-eligibility	66	72	cancer
I-eligibility	73	81	patients
I-eligibility	82	91	receiving
I-eligibility	92	100	multiple
I-eligibility	101	107	cycles
I-eligibility	108	110	of
I-eligibility	111	127	myelosuppressive
I-eligibility	128	140	chemotherapy
O	140	141	:
O	142	144	an
O	145	149	open
O	149	150	-
O	150	155	label
O	155	156	,
O	157	167	randomized
O	167	168	,
O	169	180	multicenter
O	181	186	phase
O	187	190	III
O	191	196	study
O	196	197	.

O	198	201	PEG
O	201	202	-
O	202	205	rhG
O	205	206	-
O	206	209	CSF
O	210	217	reduces
O	218	229	neutropenia
O	230	233	and
O	234	242	improves
O	243	255	chemotherapy
O	256	262	safety
O	262	263	.

O	264	266	In
B-location	267	272	China
I-location	272	273	'
I-location	273	274	s
O	275	287	registration
O	288	293	trial
O	294	295	(
O	295	299	CFDA
O	299	300	:
O	301	311	2006L01305
O	311	312	)
O	312	313	,
O	314	316	we
O	317	325	assessed
O	326	329	its
O	330	338	efficacy
O	339	342	and
O	343	349	safety
O	350	357	against
O	358	361	rhG
O	361	362	-
O	362	365	CSF
O	365	366	,
O	367	370	and
O	371	384	prospectively
O	385	393	explored
O	394	397	its
O	398	403	value
O	404	408	over
O	409	417	multiple
O	418	424	cycles
O	425	427	of
O	428	440	chemotherapy
O	440	441	.

O	442	444	In
O	445	449	this
O	450	454	open
O	454	455	-
O	455	460	label
O	460	461	,
O	462	472	randomized
O	472	473	,
O	474	485	multicenter
O	486	491	phase
O	492	493	3
O	494	499	study
O	499	500	,
O	501	507	breast
O	508	514	cancer
O	515	523	patients
O	524	525	(
O	525	526	n
O	527	528	=
B-total-participants	529	532	569
O	532	533	)
O	534	538	were
O	539	549	randomized
O	550	552	to
O	553	560	receive
O	561	564	PEG
O	564	565	-
O	565	568	rhG
O	568	569	-
O	569	572	CSF
O	573	576	100
O	577	578	µ
O	578	579	g
O	579	580	/
O	580	582	kg
O	582	583	,
O	584	587	PEG
O	587	588	-
O	588	591	rhG
O	591	592	-
O	592	595	CSF
O	596	597	6
O	598	600	mg
O	600	601	,
O	602	604	or
O	605	608	rhG
O	608	609	-
O	609	612	CSF
O	613	614	5
O	615	616	µ
O	616	617	g
O	617	618	/
O	618	620	kg
O	620	621	/
O	621	622	d
O	623	628	after
O	629	641	chemotherapy
O	641	642	.

O	643	646	The
O	647	654	primary
O	655	664	endpoints
O	665	669	were
O	670	673	the
B-outcome-Measure	674	683	incidence
I-outcome-Measure	684	687	and
I-outcome-Measure	688	696	duration
I-outcome-Measure	697	699	of
I-outcome-Measure	700	705	grade
I-outcome-Measure	706	707	3
I-outcome-Measure	707	708	/
I-outcome-Measure	708	709	4
I-outcome-Measure	710	721	neutropenia
I-outcome-Measure	722	728	during
I-outcome-Measure	729	734	cycle
I-outcome-Measure	735	736	1
O	736	737	.

O	738	747	Secondary
O	748	757	endpoints
O	758	766	included
O	767	770	the
O	771	780	incidence
O	781	784	and
O	785	793	duration
O	794	796	of
O	797	802	grade
O	803	804	3
O	804	805	/
O	805	806	4
O	807	818	neutropenia
O	819	825	during
O	826	832	cycles
O	833	834	2
O	834	835	-
O	835	836	4
O	836	837	,
O	838	841	the
B-outcome-Measure	842	851	incidence
I-outcome-Measure	852	854	of
I-outcome-Measure	855	862	febrile
I-outcome-Measure	863	874	neutropenia
O	874	875	,
O	876	879	and
O	880	883	the
B-outcome-Measure	884	890	safety
O	890	891	.

O	892	893	A
O	894	898	once
O	898	899	-
O	899	902	per
O	902	903	-
O	903	908	cycle
O	909	912	PEG
O	912	913	-
O	913	916	rhG
O	916	917	-
O	917	920	CSF
O	921	923	at
O	924	930	either
O	931	934	100
O	935	936	µ
O	936	937	g
O	937	938	/
O	938	940	kg
O	941	943	or
O	944	945	6
O	946	948	mg
O	949	952	was
O	953	956	not
O	957	966	different
O	967	971	from
O	972	977	daily
O	978	988	injections
O	989	991	of
O	992	995	rhG
O	995	996	-
O	996	999	CSF
O	1000	1003	for
O	1004	1010	either
O	1011	1020	incidence
O	1021	1023	or
O	1024	1032	duration
O	1033	1035	of
O	1036	1041	grade
O	1042	1043	3
O	1043	1044	/
O	1044	1045	4
O	1046	1057	neutropenia
O	1057	1058	.

O	1059	1072	Interestingly
O	1072	1073	,
O	1074	1075	a
O	1076	1087	substantial
O	1088	1098	difference
O	1099	1102	was
O	1103	1108	noted
O	1109	1115	during
O	1116	1121	cycle
O	1122	1123	2
O	1123	1124	,
O	1125	1128	and
O	1129	1132	the
O	1133	1143	difference
O	1144	1150	became
O	1151	1157	bigger
O	1158	1162	over
O	1163	1169	cycles
O	1170	1171	3
O	1171	1172	-
O	1172	1173	4
O	1173	1174	,
O	1175	1183	reaching
O	1184	1185	a
O	1186	1197	statistical
O	1198	1210	significance
O	1211	1213	at
O	1214	1219	cycle
O	1220	1221	4
O	1222	1224	in
O	1225	1231	either
O	1232	1241	incidence
O	1242	1243	(
O	1243	1244	P
O	1245	1246	=
O	1247	1248	0
O	1248	1249	.
O	1249	1253	0309
O	1253	1254	)
O	1255	1257	or
O	1258	1266	duration
O	1267	1268	(
O	1268	1269	P
O	1270	1271	=
O	1272	1273	0
O	1273	1274	.
O	1274	1278	0289
O	1278	1279	)
O	1280	1288	favoring
O	1289	1292	PEG
O	1292	1293	-
O	1293	1296	rhG
O	1296	1297	-
O	1297	1300	CSF
O	1300	1301	.

O	1302	1303	A
O	1304	1315	significant
O	1316	1321	trend
O	1322	1328	toward
O	1329	1330	a
O	1331	1336	lower
B-outcome	1337	1346	incidence
I-outcome	1347	1349	of
I-outcome	1350	1353	all
I-outcome	1353	1354	-
I-outcome	1354	1359	grade
I-outcome	1360	1367	adverse
I-outcome	1368	1374	events
O	1375	1378	was
O	1379	1384	noted
O	1385	1387	at
B-iv-bin-abs	1388	1391	129
O	1392	1393	(
B-iv-bin-percent	1393	1395	68
I-iv-bin-percent	1395	1396	.
I-iv-bin-percent	1396	1398	98
I-iv-bin-percent	1398	1399	%
O	1399	1400	)
O	1400	1401	,
B-iv-bin-abs	1402	1405	142
O	1406	1407	(
B-iv-bin-percent	1407	1409	75
I-iv-bin-percent	1409	1410	.
I-iv-bin-percent	1410	1412	53
I-iv-bin-percent	1412	1413	%
O	1413	1414	)
O	1414	1415	,
O	1416	1419	and
B-cv-bin-abs	1420	1423	160
O	1424	1425	(
B-cv-bin-percent	1425	1427	82
I-cv-bin-percent	1427	1428	.
I-cv-bin-percent	1428	1430	47
I-cv-bin-percent	1430	1431	%
O	1431	1432	)
O	1433	1435	in
O	1436	1439	the
O	1440	1443	PEG
O	1443	1444	-
O	1444	1447	rhG
O	1447	1448	-
O	1448	1451	CSF
O	1452	1455	100
O	1456	1457	µ
O	1457	1458	g
O	1458	1459	/
O	1459	1461	kg
O	1462	1465	and
O	1466	1467	6
O	1468	1470	mg
O	1471	1474	and
O	1475	1478	rhG
O	1478	1479	-
O	1479	1482	CSF
O	1483	1489	groups
O	1489	1490	,
O	1491	1503	respectively
O	1504	1505	(
O	1505	1506	P
O	1507	1508	=
O	1509	1510	0
O	1510	1511	.
O	1511	1515	0085
O	1515	1516	)
O	1516	1517	.

O	1518	1521	The
O	1522	1535	corresponding
B-outcome	1536	1545	incidence
I-outcome	1546	1548	of
I-outcome	1549	1554	grade
I-outcome	1555	1556	3
I-outcome	1556	1557	/
I-outcome	1557	1558	4
I-outcome	1559	1563	drug
I-outcome	1563	1564	-
I-outcome	1564	1571	related
I-outcome	1572	1579	adverse
I-outcome	1580	1586	events
O	1587	1590	was
B-iv-bin-abs	1591	1592	2
O	1592	1593	/
B-intervention-participants	1593	1596	187
O	1597	1598	(
B-iv-bin-percent	1598	1599	1
I-iv-bin-percent	1599	1600	.
I-iv-bin-percent	1600	1602	07
I-iv-bin-percent	1602	1603	%
O	1603	1604	)
O	1604	1605	,
B-iv-bin-abs	1606	1607	1
O	1607	1608	/
B-intervention-participants	1608	1611	188
O	1612	1613	(
B-iv-bin-percent	1613	1614	0
I-iv-bin-percent	1614	1615	.
I-iv-bin-percent	1615	1617	53
I-iv-bin-percent	1617	1618	%
O	1618	1619	)
O	1619	1620	,
O	1621	1624	and
B-cv-bin-abs	1625	1626	8
O	1626	1627	/
B-control-participants	1627	1630	194
O	1631	1632	(
B-cv-bin-percent	1632	1633	4
I-cv-bin-percent	1633	1634	.
I-cv-bin-percent	1634	1636	12
I-cv-bin-percent	1636	1637	%
O	1637	1638	)
O	1638	1639	,
O	1640	1652	respectively
O	1653	1654	(
O	1654	1655	P
O	1656	1657	=
O	1658	1659	0
O	1659	1660	.
O	1660	1664	0477
O	1664	1665	)
O	1665	1666	.

O	1667	1679	Additionally
O	1679	1680	,
O	1681	1684	PFS
O	1685	1687	in
O	1688	1698	metastatic
O	1699	1707	patients
O	1708	1717	preferred
O	1718	1721	PEG
O	1721	1722	-
O	1722	1725	rhG
O	1725	1726	-
O	1726	1729	CSF
O	1730	1732	to
O	1733	1736	rhG
O	1736	1737	-
O	1737	1740	CSF
O	1741	1748	despite
O	1749	1751	no
O	1752	1764	significance
O	1765	1773	observed
O	1774	1776	by
O	1777	1783	Kaplan
O	1783	1784	-
O	1784	1789	Meier
O	1790	1798	analysis
O	1799	1800	(
O	1800	1801	n
O	1802	1803	=
O	1804	1806	49
O	1806	1807	,
O	1808	1809	P
O	1810	1811	=
O	1812	1813	0
O	1813	1814	.
O	1814	1817	153
O	1817	1818	)
O	1818	1819	.

O	1820	1823	PEG
O	1823	1824	-
O	1824	1827	rhG
O	1827	1828	-
O	1828	1831	CSF
O	1832	1834	is
O	1835	1836	a
O	1837	1841	more
O	1842	1852	convenient
O	1853	1856	and
O	1857	1861	safe
O	1862	1873	formulation
O	1874	1877	and
O	1878	1879	a
O	1880	1884	more
O	1885	1894	effective
O	1895	1907	prophylactic
O	1908	1915	measure
O	1916	1918	in
O	1919	1925	breast
O	1926	1932	cancer
O	1933	1941	patients
O	1942	1951	receiving
O	1952	1960	multiple
O	1961	1967	cycles
O	1968	1970	of
O	1971	1983	chemotherapy
O	1983	1984	.
